Ambea AB

Ambea reported an adjusted earnings per share of SEK 2.13 (+88%) and an adjusted EBITA of SEK 397m (+28%) for Q2 2026. The rolling 12-month EBITDA margin reached 10.0% and free cash flow rose to SEK 929m. Net sales grew by 7% (organic 4.4%), leverage fell to 2.4x EBITDA and the stock climbed close to a 52-week high. Management highlights a strong pipeline of over 2,200 new care places, continued bolt-on acquisitions and the scheduled takeover offer for Humana. » More on de.investing.com

Ambea reports Q3 2025 net sales growth of 16%, driven by acquisitive growth of 13.2% and 3.5% organic growth. Adjusted EBITA rose 19% to 570 MSEK and the EBITA margin improved to 13.9%; adjusted diluted earnings per share for 12 months increased significantly to 10.38. The company is expanding its pipeline and entering Finland via the Validia acquisition (about 90 MSEK in annual net sales), reports strong free cash flow of 696 MSEK and has launched a share buyback program while giving a positive outlook. » More on de.investing.com

Ambea reports a 16.2% increase in net sales for Q2 2025, driven by organic growth and acquisitions including the purchase of Validia, and met all financial targets. EBITDA rose 15% and the share price jumped 9.04% after the announcement; management plans further growth through acquisitions and expansion of care places in Finland. Risks remain around the integration of Validia as well as the competitive and macroeconomic environment. » More on de.investing.com